<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:44:19Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6537706" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6537706</identifier>
        <datestamp>2019-06-05</datestamp>
        <setSpec>eid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id>
              <journal-id journal-id-type="publisher-id">EID</journal-id>
              <journal-title-group>
                <journal-title>Emerging Infectious Diseases</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1080-6040</issn>
              <issn pub-type="epub">1080-6059</issn>
              <publisher>
                <publisher-name>Centers for Disease Control and Prevention</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6537706</article-id>
              <article-id pub-id-type="pmcid">PMC6537706</article-id>
              <article-id pub-id-type="pmc-uid">6537706</article-id>
              <article-id pub-id-type="pmid">31107231</article-id>
              <article-id pub-id-type="pmid">31107231</article-id>
              <article-id pub-id-type="publisher-id">18-1620</article-id>
              <article-id pub-id-type="doi">10.3201/eid2506.181620</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="article-type">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="TOC-title">
                  <subject>Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease</article-title>
                <alt-title alt-title-type="running-head">Single-Injection Vaccine to Protect Against NiV</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mire</surname>
                    <given-names>Chad E.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Geisbert</surname>
                    <given-names>Joan B.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Agans</surname>
                    <given-names>Krystle N.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Versteeg</surname>
                    <given-names>Krista M.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Deer</surname>
                    <given-names>Daniel J.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Satterfield</surname>
                    <given-names>Benjamin A.</given-names>
                  </name>
                  <xref rid="FN1" ref-type="fn">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fenton</surname>
                    <given-names>Karla A.</given-names>
                  </name>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Geisbert</surname>
                    <given-names>Thomas W.</given-names>
                  </name>
                </contrib>
                <aff id="aff1">Galveston National Laboratory, Galveston, Texas, USA; University of Texas Medical Branch, Galveston</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Address for correspondence: Thomas W. Geisbert, University of Texas Medical Branch, Microbiology and Immunology, 301 University Blvd, Galveston, TX 77550-0610, USA; email: <email xlink:href="twgeisbe@utmb.edu">twgeisbe@utmb.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2019</year>
              </pub-date>
              <volume>25</volume>
              <issue>6</issue>
              <fpage>1144</fpage>
              <lpage>1152</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiV<sub>M</sub>), discovered in 1998–1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiV<sub>B</sub>), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiV<sub>B</sub> in African green monkeys resulted in a more severe and lethal disease than NiV<sub>M</sub>. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiV<sub>B</sub> challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiV<sub>B</sub> model of human infection.</p>
              </abstract>
              <kwd-group kwd-group-type="author">
                <title>Keywords: </title>
                <kwd>Nipah virus</kwd>
                <kwd>Henipavirus</kwd>
                <kwd>vaccines</kwd>
                <kwd>nonhuman primates</kwd>
                <kwd>viruses</kwd>
                <kwd>zoonoses</kwd>
                <kwd>vesicular stomatitis virus</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <p>Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic zoonotic agents in the paramyxovirus genus <italic>Henipavirus</italic>. Human case-fatality rates (CFRs) for these viruses historically have ranged from 40% to &gt;90% (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>). NiV is categorized as a Biosafety Level 4 (BSL-4) pathogen because of the substantial illness and death it causes and the lack of approved vaccines and therapeutic drugs for human use. In 2015, the World Health Organization listed NiV as a priority pathogen because it is likely to cause severe outbreaks and, in early 2018, placed NiV on the Blueprint list of priority diseases (<ext-link xlink:href="https://www.who.int/blueprint/priority-diseases" ext-link-type="uri">https://www.who.int/blueprint/priority-diseases</ext-link>). This WHO designation was bolstered because of a deadly NiV outbreak (CFR 89%) during spring 2018 in southwestern India, where NiV had not previously been reported (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>).</p>
            <p>Bats of the genus <italic>Pteropus</italic> are the primary reservoir in nature for NiV (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>), but several other mammal species can be infected by NiV (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>–<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). Analysis of NiV genomes has identified 2 NiV strains responsible for outbreaks: Malaysia strain NiV<sub>M</sub> and Bangladesh strain (NiV<sub>B</sub>). NiV<sub>M</sub> caused the first identified outbreak of NiV during 1998–1999 in Malaysia and Singapore (≈270 persons infected; CFR ≈40%) (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>,<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>) and perhaps was responsible for a 2014 outbreak in the Philippines (CFR ≈52%); however, this speculation is based on short genomic reads, so the NiV strain that caused this outbreak is not known (<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>). NiV<sub>B</sub> has caused repeated outbreaks in Bangladesh and northeastern India; outbreaks occurred almost every year during 2001–2015 (<xref rid="R11" ref-type="bibr"><italic>11</italic></xref>–<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>). These NiV<sub>B</sub> outbreaks had higher CFRs, averaging ≈80% (<xref rid="R14" ref-type="bibr"><italic>14</italic></xref>), and showed documented human-to-human transmission (<xref rid="R11" ref-type="bibr"><italic>11</italic></xref>,<xref rid="R16" ref-type="bibr"><italic>16</italic></xref>).</p>
            <p>Eight experimental preventive candidate vaccines against henipaviruses have been evaluated in NiV<sub>M</sub> animal models: 1) canarypox and 2) vaccinia viruses encoding the NiV<sub>M</sub> fusion protein (F) or the NiV<sub>M</sub> attachment protein (G) that have shown protection against NiV<sub>M</sub> in hamsters and pigs (<xref rid="R17" ref-type="bibr"><italic>17</italic></xref>,<xref rid="R18" ref-type="bibr"><italic>18</italic></xref>); 3) a recombinant adeno-associated vaccine expressing the NiV<sub>M</sub> G protein that completely protected hamsters against homologous NiV<sub>M</sub> challenge (<xref rid="R19" ref-type="bibr"><italic>19</italic></xref>); 4) recombinant vesicular stomatitis viruses (rVSVs) expressing the NiV<sub>M</sub> F protein or the NiV<sub>M</sub> G protein that had 100% efficacy in hamsters against NiV<sub>M</sub> (<xref rid="R20" ref-type="bibr"><italic>20</italic></xref>); 5) rVSVs expressing the NiV<sub>B</sub> F protein or the NiV<sub>B</sub> G protein that completely protected ferrets from NiV<sub>M</sub> disease (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>); 6) an rVSV expressing the Zaire ebolavirus (EBOV) glycoprotein (GP) and the NiV<sub>M</sub> G protein (rVSV-EBOV-GP-NiVG) that demonstrated efficacy in NiV<sub>M</sub> hamster (<xref rid="R22" ref-type="bibr"><italic>22</italic></xref>) and African green monkey (<italic>Chlorocebus aethiops</italic>) (<xref rid="R23" ref-type="bibr"><italic>23</italic></xref>) models; 7) a recombinant measles virus vector expressing the NiV<sub>M</sub> G protein that had efficacy in the NiV<sub>M</sub> African green monkey model (<xref rid="R24" ref-type="bibr"><italic>24</italic></xref>); and 8) a recombinant subunit vaccine based on the HeV G protein (sG<sub>HeV</sub>) that completely protected small animals against lethal HeV and NiV<sub>M</sub> infections (<xref rid="R25" ref-type="bibr"><italic>25</italic></xref>–<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>) and was efficacious in the robust African green monkey model of HeV (<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>) and NiV<sub>M</sub> infection (<xref rid="R29" ref-type="bibr"><italic>29</italic></xref>). Of 8 vaccines, the sG<sub>HeV</sub> vaccine is furthest along in evaluation; it has received licensure as a veterinary vaccine for HeV in horses (Equivac HeV, Zoetis, <ext-link xlink:href="https://www.zoetis.com" ext-link-type="uri">https://www.zoetis.com</ext-link>) in Australia and is being considered as a human vaccine against NiV. When tested against NiV, these 8 vaccine vectors have been tested only against NiV<sub>M</sub> infection in animal models, and although the antigenicity of these vaccines should not be a concern given that HeV G is an immunogen against NiV<sub>M</sub> infection, there are new data on the NiV<sub>B</sub> African green monkey model to consider as far as dose/regimen of vaccines. </p>
            <p>NiV<sub>B</sub> infection in African green monkeys is more pathogenic than NiV<sub>M</sub> infection (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). This difference resulted in significantly reduced efficacy of antibody therapy because of temporal differences in viral load. Specifically, the human monoclonal antibody m102.4 that had been shown to completely protect African green monkeys against lethal NiV<sub>M</sub> disease when treatment was delayed until day 5 after virus exposure provided no protection when African green monkeys were challenged with NiV<sub>B</sub> and treated beginning at day 5 after virus challenge (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>,<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>). Considering these new data, the current vaccines against NiV need to be evaluated for possible differences in dose/regimen against the more pathogenic NiV<sub>B</sub> infection in the robust African green monkey model. To assess single-dose vaccine efficacy, we evaluated the rVSV vaccine vectors expressing either the NiV<sub>B</sub> F or NiV<sub>B</sub> G proteins 28 days after a single-dose vaccination in the NiV<sub>B</sub> African green monkey model, which most faithfully recapitulates human disease (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>rVSV Vaccine Vectors and NiV<sub>B</sub> Challenge Stock</title>
                <p>We recovered the rVSV NiV<sub>B</sub> vaccines (rVSV-ΔG-NiV<sub>B</sub>/F-GFP and rVSV-ΔG-NiV<sub>B</sub>/G-GFP) and rVSV-ΔG-GFP using methods as previously described (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>,<xref rid="R32" ref-type="bibr"><italic>32</italic></xref>). The isolate of NiV<sub>B</sub> used in this vaccine study was obtained from a fatal human case (200401066) described previously (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p>
              </sec>
              <sec>
                <title>Statistical Analyses</title>
                <p>Animal studies in BSL-4 and nonhuman primate work generally restrict the number of animals used, the volume of biological samples that can be obtained, and the ability to repeat assays independently and thus limit statistical analysis. Consequently, we present these data as the mean calculated from replicate samples, not replicate assays, and error bars represent SD across replicates (<xref rid="F1" ref-type="fig">Figure 1</xref>, panels B, C, D).</p>
                <fig position="float" id="F1" fig-type="figure">
                  <label>Figure 1</label>
                  <caption>
                    <p>Groups of African green monkeys (<italic>Chlorocebus aethiops</italic>) receiving recombinant vesicular stomatitis virus (rVSV) vaccine against Nipah virus Bangladesh strain (NiV<sub>B</sub>). Triangles indicate days of vaccination; arrows indicate days of sampling; and asterisk (*) indicates day of challenge. Red indicates control group (G<sub>Ind</sub>*rVSV-ΔG-GFP expressing no glycoprotein); blue indicates F group (G<sub>Ind</sub>* rVSV-NiV<sub>B</sub>/F-GFP expressing the NiV<sub>B</sub> F protein); yellow indicates G group (G<sub>Ind</sub>*rVSV-NiV<sub>B</sub> /G-GFP expressing the NiV<sub>B</sub> G protein); F/G group (single-cycle infectious virions with NiV<sub>B</sub> F and G proteins on the cell surface). F, fusion; G, attachment</p>
                  </caption>
                  <graphic xlink:href="18-1620-F1" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Animal Ethics Considerations and Experiments</title>
                <p>Healthy adult African green monkeys were handled in the animal BSL-4 containment space at the Galveston National Laboratory (Galveston, TX, USA). Research was approved under animal protocol 1310040 by the University of Texas Medical Branch Institutional Animal Care and Use Committee (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>).</p>
                <p>We used 10 adult African green monkeys weighing 3.5–6.0 kg in this study. One animal served as control (received G<sub>In</sub>* rVSV-ΔG-GFP), and 3 animals per vaccine group received G* rVSV-ΔG-NiV<sub>B</sub>/F-GFP, G* rVSV-ΔG-NiV<sub>B</sub>/G-GFP, or rVSVΔG-NiV<sub>B</sub>/F/G. For vaccination, animals were anesthetized with ketamine and vaccinated with ≈10<sup>7</sup> PFU by intramuscular injection (day −28). Twenty-eight days after vaccination, the animals were exposed to ≈5 × 10<sup>5</sup> PFU of NiV<sub>B</sub>; the dose was equally divided between the intratracheal and the intranasal routes for each animal. Animals were monitored for clinical signs of illness (i.e., temperature, respiration quality, blood count, and clinical pathologic findings) at 0, 3, 6, 8, 10, 15, 21, and 28 days postchallenge (dpc).</p>
              </sec>
              <sec>
                <title>NiV<sub>B</sub> Serum Neutralization Assays</title>
                <p>We determined neutralization titers against NiV<sub>B</sub> using a conventional serum neutralization assay. In brief, we serially diluted serum 5-fold or 2-fold depending on magnitude of neutralization titers and incubated with ≈100 PFU of NiV<sub>B</sub> for 1 h at 37°C, as previously described (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p>
              </sec>
              <sec>
                <title>RNA Isolation from NiV<sub>B</sub>-Infected African green monkeys</title>
                <p>We isolated RNA from NiV<sub>B</sub>-infected animals as described previously (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). For viremia, we added 100 μL of blood to 600 μL of AVL viral lysis buffer (QIAGEN, <ext-link xlink:href="https://www.qiagen.com" ext-link-type="uri">https://www.qiagen.com</ext-link>) for RNA extraction. For virus load in tissue, we stored ≈100 mg in 1 mL RNAlater (QIAGEN) for 7 d to stabilize RNA, removed the RNAlater completely, and homogenized tissues in 600 μL RLT buffer (QIAGEN) in a 2-mL cryovial using a tissue lyser (QIAGEN) and ceramic beads.</p>
              </sec>
              <sec>
                <title>Detection of NiV<sub>B</sub> Load</title>
                <p>We isolated RNA from blood or tissues and assessed it using primers and probe targeting the N gene and the intergenic region between N and P genes of NiV<sub>B</sub> for quantitative reverse transcription PCR (qRT-PCR). The probe used was 6FAM-5′CGT CAC ACA TCA GCT CTG ACA A 3′-6TAMRA (Life Technologies, <ext-link xlink:href="https://www.thermofisher.com" ext-link-type="uri">https://www.thermofisher.com</ext-link>), as described previously (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p>
              </sec>
              <sec>
                <title>Hematology and Serum Biochemistry</title>
                <p>We assessed clinical pathology of NiV<sub>B</sub>-infected African green monkeys by hematology and serum biochemistry analysis as described previously (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). We performed the hematology assays using a laser-based hematologic analyzer (Beckman Coulter, <ext-link xlink:href="https://www.beckmancoulter.com" ext-link-type="uri">https://www.beckmancoulter.com</ext-link>) and serum biochemistry analysis using a Piccolo point-of-care analyzer and Biochemistry Panel Plus analyzer discs (Abaxis, <ext-link xlink:href="https://www.abaxis.com" ext-link-type="uri">https://www.abaxis.com</ext-link>). </p>
              </sec>
              <sec>
                <title>Histopathology and Immunohistochemistry</title>
                <p>We performed necropsies on all animals and collected tissue samples of all major organs. We performed histopathologic and immunohistochemical examination and analyses as described previously (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Immunization of African Green Monkeys and Measuring the Humoral Immune Response</title>
                <p>Previously, single-injection, single-round replication rVSV vaccine vectors expressing the NiV<sub>B</sub> F or NiV<sub>B</sub> G proteins were described, characterized, and shown to be efficacious against NiV<sub>B</sub> challenge in ferrets (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>). To assess the efficacy of these vectors in the NiV<sub>B</sub> African green monkey model, 4 groups of African green monkeys received a single intramuscular vaccination of rVSV vectors on day −28 (<xref rid="F2" ref-type="fig">Figure 2</xref>). To analyze the antibody response to rVSV-ΔG-NiV<sub>B</sub> vaccinations, we assessed circulating antibodies for neutralization activity against NiV<sub>B</sub> before and after vaccination by using a 50% plaque-reduction neutralization titer (PRNT<sub>50</sub>) assay. All 4 groups had no detectable neutralizing antibody titers before vaccination (<xref rid="T1" ref-type="table">Table 1</xref>, day −28). On the day of challenge, the control animal (C-1) did not have detectable neutralizing antibody titers against NiV<sub>B</sub>, whereas all animals from the specific NiV protein vaccination groups (F, G, and F/G) had detectable neutralizing antibodies against NiV<sub>B</sub> (<xref rid="T1" ref-type="table">Table 1</xref>, day 0). Overall, the detectable neutralizing antibody response against NiV<sub>B</sub> reached a 1:640 dilution titer in the G and F/G groups and from 1:160 to 1:640 in the F group.</p>
                <fig position="float" id="F2" fig-type="figure">
                  <label>Figure 2</label>
                  <caption>
                    <p>Protection of African green monkeys (<italic>Chlorocebus aethiops</italic>) from Nipah virus Bangladesh strain (NiV<sub>B</sub>)–mediated disease and viral load. A) Kaplan-Meier survival curve for each vaccine group and historical controls after NiV<sub>B</sub> challenge: controls (vaccine, n = 1; historical, n = 14), F group (n = 3), G group (n = 3), and F/G group (n = 3). C–D) Viral load in the animals as detected by NiV<sub>B</sub> GEq by reverse transcription quantitative PCR from nasal swab samples: as GEq per swab (B), oral swab samples as GEq per swab (C), and blood as GEq/mL (D). Red, control group (G<sub>Ind</sub>*rVSV-ΔG-GFP expressing no glycoprotein); blue, F group (G<sub>Ind</sub>* rVSV-NiV<sub>B</sub> /F-GFP expressing the NiV<sub>B</sub> F protein); yellow, G group (G<sub>Ind</sub>*rVSV-NiV<sub>B</sub>/G-GFP expressing the NiV<sub>B</sub> G protein); green, F/G group (single-cycle infectious virions with NiV<sub>B</sub> F and G proteins on the cell surface). Error bars indicate SD. C, control; F, fusion; G, attachment; GEq, genome equivalent.</p>
                  </caption>
                  <graphic xlink:href="18-1620-F2" position="float"/>
                </fig>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <title>NiV<sub>B</sub> Serum neutralization titers in vaccinated African green monkeys (<italic>Chlorocebus aethiops</italic>)* </title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="63" span="1"/>
                    <col width="58" span="1"/>
                    <col width="45" span="1"/>
                    <col width="34" span="1"/>
                    <col width="36" span="1"/>
                    <thead>
                      <tr>
                        <th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Vaccine</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Animal no.</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Day −28†</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Day 0†</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Day 28†</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">None<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">C-1<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">40‡<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F only vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">1,280</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                        <td valign="top" align="center" rowspan="1" colspan="1">F-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">160</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">2,560</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">
                          <hr/>
                        </td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F-3<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">320<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">5,120<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">G only vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">G-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">5,120</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                        <td valign="top" align="center" rowspan="1" colspan="1">G-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">5,120</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">
                          <hr/>
                        </td>
                        <td valign="top" align="center" rowspan="1" colspan="1">G-3<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">5,120<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F+G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F/G-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">2,560</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                        <td valign="top" align="center" rowspan="1" colspan="1">F/G-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">5,120</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                        <td valign="top" align="center" rowspan="1" colspan="1">F/G-3</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">&lt;20</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">640</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">2,560</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>*Titers are reciprocal serum dilution at which 50% of virus was neutralized. NiV, Nipah virus; NiV<sub>B</sub>, NiV Bangladesh strain. †Day postchallenge. ‡Terminal day 8 postchallenge.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>NiV<sub>B</sub> Challenge and Viral Load of Vaccinated African Green Monkeys</title>
                <p>To determine the efficacy of the rVSV-ΔG-NiV<sub>B</sub> vectors against NiV<sub>B</sub> disease in African green monkeys, we challenged these animals by combined intratracheal and intranasal routes with a lethal challenge dose of NiV<sub>B</sub> on day 0 (<xref rid="F1" ref-type="fig">Figure 1</xref>). All African green monkeys were closely monitored for up to 28 dpc for clinical signs of illness. The NiV<sub>B</sub> antigen vaccinated animals in the F (F-1–3), G (G-1–3), and F/G (F/G-1–3) groups showed no signs of clinical illness (<xref rid="T2" ref-type="table">Table 2</xref>) and were 100% protected against NiV<sub>B</sub> challenge (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel A), whereas the animal in the nonspecific vaccinated control group (C-1) exhibited clinical signs of disease (<xref rid="T2" ref-type="table">Table 2</xref>) and died of infection on day 8 (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel A). In addition, the control animal was the only NiV<sub>B</sub>-infected animal to have lymphopenia and serosanguinous nasal discharge during the course of disease (<xref rid="T2" ref-type="table">Table 2</xref>).</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <title>Clinical findings and outcome of Nipah virus Bangladesh strain–challenged African green monkeys*</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="45" span="1"/>
                    <col width="27" span="1"/>
                    <col width="63" span="1"/>
                    <col width="85" span="1"/>
                    <col width="261" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Animal no.</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Sex</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Group</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Clinical illness</th>
                        <th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Clinical and gross pathology findings†</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">C-1<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Control ΔG vaccine<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Loss of appetite (d 6–8); labored breathing (d 6–8). Died on d 8.<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Lymphopenia (d 6); serosanguinous nasal and oral discharge (d 8), serosanguinous pleural fluid, severely inflated, enlarged lungs with severe congestion and hemorrhage of all lobes, multifocal to coalescing hemorrhage of the mucosal surface of the urinary bladder.<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Thrombocytopenia (d 15); &gt;3 fold increase in ALT (d 6), &gt;3 fold increase in AST</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F-3<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F vaccine<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Increase in CRP (d 6)<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">G-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">G-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">G-3<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">G vaccine<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None<hr/></td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None<hr/></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F/G-1</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F + G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Increase in CRP (d 8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F/G-2</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F + G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Thrombocytopenia (d 21, d 28); increase in CRP (d 8, d 10, d 15)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">F/G-3</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">M</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">F + G vaccine</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">None</td>
                        <td valign="top" align="center" rowspan="1" colspan="1">Thrombocytopenia (d 8)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein. †Lymphopenia is defined as a <underline>&gt;</underline>30% decrease in number of lymphocytes; thrombocytopenia is defined as a <underline>&gt;</underline>30% decrease in number of platelets. </p>
                  </table-wrap-foot>
                </table-wrap>
                <p>To determine the level of NiV<sub>B</sub> replication in animals after challenge, we assessed viral load by qRT-PCR on nasal and oral swab samples and whole blood samples (<xref rid="F1" ref-type="fig">Figure 1</xref>, panels B–D). We detected NiV<sub>B</sub> genome equivalents (GEq) from nasal swab samples (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel B) in the control, F, G, and F/G groups. The following animals were positive for viral RNA: C-1 at 6 dpc; F-1 at 3 dpc; F-2 at 3, 6, and 10 dpc; G-1 at 3 dpc; G-3 at 6 dpc; F/G-1 at 3, 6, and 8 dpc; and F/G-3 at 3 dpc. At 6 dpc, when C-1 was positive for NiV RNA in nasal swab samples, the levels were &gt;1 log higher than they were for the NiV-antigen vaccinated groups F, G, and F/G. Oral swab samples were negative for NiV RNA in all animals in the G-vaccinated group (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel C), and NiV<sub>B</sub> GEq were detected from oral swab samples in the control, F, and F/G groups. The following animals were positive for viral RNA: C-1 at 3 and 6 dpc, F-1 at 3 dpc, and F/G-1 at 3 and 6 dpc. Within these oral swab sample results, C-1 had NiV RNA levels up to 100-fold higher than the F and F/G animals that had positive oral swab samples (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel C). Unlike the results for swab samples, which represent tissues initially exposed to NiV, systemic and circulating NiV<sub>B</sub> GEq were not detected in whole blood from animals in the F, G, and F/G groups, whereas the control animal was positive in the blood sample from 6 dpc (<xref rid="F1" ref-type="fig">Figure 1</xref>, panel D). The lack of systemic and circulating detection of NiV<sub>B</sub> RNA correlated with survival (<xref rid="T2" ref-type="table">Table 2</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>, panel A).</p>
              </sec>
              <sec>
                <title>Gross Pathologic, Histopathologic, and Immunohistochemical Analyses of NiV<sub>b</sub>-Infected African Green Monkeys</title>
                <p>In the F, G, and F/G groups, we observed no gross pathologic findings at study endpoint. However, in the control animal that died of NiV<sub>B</sub> infection, gross pathologic findings included serosanguinous pleural effusion, failure of all lung lobes to collapse with severe pulmonary hemorrhage and congestion, and multifocal to coalescing hemorrhage of the mucosal surface of the urinary bladder.</p>
                <p>Lung sections examined from the control animal had moderate lymphoplasmacytic interstitial pneumonia characterized by a diffuse thickening of alveolar septae by moderate numbers of lymphocytes, plasma cells, polymerized fibrin, and edema fluid. The alveolar spaces were flooded by edema fluid, polymerized fibrin, foamy alveolar macrophages, and cellular debris. Endothelial syncytial cells were most apparent in medium- to small-caliber vessels (<xref rid="F3" ref-type="fig">Figure 3</xref>, panel A). The animals in the F, G, and F/G groups had no major histologic findings in the lung sections (<xref rid="F3" ref-type="fig">Figure 3</xref>, panels C, E, G). Immunohistochemical analysis revealed strong NiV antigen immunoreactivity within scattered alveolar macrophages and the endothelium of the alveolar septae and syncytial cells within medium to small caliber vessels in up to ≈75% of the examined pulmonary tissues (<xref rid="F3" ref-type="fig">Figure 3</xref>, panel B). The lung sections of the F, G, and F/G groups were devoid of detectable NiV antigen (<xref rid="F3" ref-type="fig">Figure 3</xref>, panels D, F, H).</p>
                <fig position="float" id="F3" fig-type="figure">
                  <label>Figure 3</label>
                  <caption>
                    <p>Results of testing for Nipah virus (NiV) in lung tissue from representative vaccinated African green monkeys (<italic>Chlorocebus aethiops</italic>). A, C, E, G) Hematoxylin and eosin staining; B, D, F, H) immunohistochemistry of tissues labeled with NiV N protein–specific polyclonal rabbit antibody. In stained tissue from the control animal (A), diffuse thickening of alveolar septae by moderate numbers of lymphocytes, plasma cells, polymerized fibrin, and edema fluid within the alveolar spaces were found; stained sections examined from the NiV F (C), NiV G (E), and NiV F/G (G) groups were unremarkable in comparison with sections from the control animal. In antibody-labeled tissue from the control animal (B), strong immunolabeling for NiV antigen with alveolar septae, scattered alveolar macrophages, and the endothelium of small caliber vessels were found, including syncytial cells with strong cytoplasmic immunolabeling for NiV antigen; no immunolabeling for NiV antigen was identified from the NiV F (D), NiV G (F), and NiV F/G (H) groups. Original magnification ×20.</p>
                  </caption>
                  <graphic xlink:href="18-1620-F3" position="float"/>
                </fig>
                <p>Spleen sections from the control animal were depleted of lymphocytes in the multifocal follicular germinal centers within the splenic white pulp and were effaced by hemorrhage, fibrin, syncytial cell formation (<xref rid="F4" ref-type="fig">Figure 4</xref>, panel A). Spleens from the F, G, and F/G groups had no major histologic findings (<xref rid="F4" ref-type="fig">Figure 4</xref>, panels C, E, G). Immunohistochemical analysis of the spleen from the control animal revealed strong immunoreactivity for NiV antigen within the endothelium, syncytial cells, and scattered mononuclear cells in up to ≈50% of the examined splenic tissue (<xref rid="F4" ref-type="fig">Figure 4</xref>, panel B), whereas the spleen sections of groups F, G, and F/G were devoid of detectable NiV antigen (<xref rid="F4" ref-type="fig">Figure 4</xref>, panels D, F, H).</p>
                <fig position="float" id="F4" fig-type="figure">
                  <label>Figure 4</label>
                  <caption>
                    <p>Results of testing for Nipah virus (NiV) in spleen tissue from representative vaccinated African green monkeys (<italic>Chlorocebus aethiops</italic>). A, C, E, G) Hematoxylin and eosin staining; B, D, F, H) immunohistochemistry of tissues labeled with NiV N protein–specific polyclonal rabbit antibody. In stained tissue from the control animal (A), moderate necrosis and drop out of the white pulp (*), with hemorrhage, and fibrin within germinal centers are seen; stained sections examined from the NiV F (C), NiV G (E), and NiV F/G (G) groups were devoid of any significant lesions compared with sections from the control animal. In antibody-labeled tissues from the control animal (B), strong immunolabeling for NiV antigen with scattered mononuclear cells (white arrow) and syncytial cells within germinal centers were found, and the endothelium of small caliber vessels had strong cytoplasmic immunolabeling for NiV antigen; no immunolabeling for NiV antigen was identified from the NiV F (D), NiV G (F), and NiV F/G (H) groups. Original magnification ×20.</p>
                  </caption>
                  <graphic xlink:href="18-1620-F4" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>An important step in the preclinical development of a vaccine is efficacy testing in standards of animal models of disease. For NiV, the standard is the African green monkey model. Although the initial studies on the NiV<sub>M</sub> model in African green monkeys were reported as near uniformly lethal, data from several groups have revealed the model is not 100% lethal, depending on dose and route of infection (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R24" ref-type="bibr"><italic>24</italic></xref>,<xref rid="R29" ref-type="bibr"><italic>29</italic></xref>–<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>,<xref rid="R33" ref-type="bibr"><italic>33</italic></xref>,<xref rid="R34" ref-type="bibr"><italic>34</italic></xref>). Combining the control animals from these studies, in which African green monkeys were challenged with various combinations of routes (e.g., intratracheal, intranasal, intraperitoneal, oral, small particle aerosol) at various doses, revealed that 18 (72%) of 25 animals died; however, most of the control animals were positive for circulating NiV RNA and had signs of clinical disease to varying degrees. Historically, our previous studies with the NiV<sub>B</sub> model has resulted in the deaths of all 14 control African green monkeys; the mean time to death was 7.14 days (<xref rid="F2" ref-type="fig">Figure 2</xref>, panel A). We recently compared the pathogenesis of NiV<sub>M</sub> and NiV<sub>B</sub> strains in African green monkeys and observed that NiV<sub>B</sub> caused more pulmonary and splenic pathologic findings (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). We also observed the efficacy of time to treatment post-NiV challenge with a human monoclonal antibody m102.4 was shorter for NiV<sub>B</sub>-infected animals than for NiV<sub>M</sub>-infected animals (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). With these animal data in mind and the fact that NiV<sub>B</sub> has been responsible for most NiV outbreaks since 2002, we wanted to test our rVSV NiV vaccine vectors expressing NiV<sub>B</sub> F and G proteins as immunogens, which had 100% efficacy against NiV<sub>M</sub> challenge in ferrets (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>), against NiV<sub>B</sub> challenge in African green monkeys.</p>
              <p>In this study, we vaccinated 1 control African green monkey with a nonglycoprotein rVSV vector control, G<sub>Ind</sub>* rVSV-ΔG-GFP, and 3 groups of 3 African green monkeys with NiV antigen vectors: G<sub>Ind</sub>* rVSV-ΔG-NiV<sub>B</sub>/F-GFP, G<sub>Ind</sub>* rVSV-ΔG-NiV<sub>B</sub>/G-GFP, or G<sub>Ind</sub>* rVSV-ΔG-NiV<sub>B</sub>/F/G-GFP. The control animal, C-1, did not develop NiV<sub>B</sub> neutralizing antibodies by the day of challenge; had detectable circulating NiV RNA at 6 dpc; had clinical signs of NiV-mediated disease; and ultimately died of infection, showing typical NiV gross pathology and histopathologic findings. Conversely, the 3 rVSV NiV vaccine groups had animals in which detectable circulating NiV F, G, or F and G IgG developed, and circulating neutralizing antibody titers developed in all 3 groups by 28 days postvaccination. Each vaccine cohort had detectable NiV<sub>B</sub> RNA in nasal swab samples and only the F and F/G groups in oral swab samples, but none of the cohorts had any detectable circulating NiV<sub>B</sub> RNA throughout the course of the study. Consistent with the vaccine response from each cohort and the control of systemic spread of NiV<sub>B</sub> infection and control of NiV-mediated disease, all of the specifically vaccinated African green monkeys survived NiV<sub>B</sub> challenge.</p>
              <p>The results of this study are similar to what we observed with these rVSV NiV constructs in the ferret model, which showed 100% protection regardless of the vaccine construct (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>). Differences were that we found higher PRNT<sub>50</sub> results for neutralizing antibody titers on day of challenge in this study and detected no circulating NiV RNA in the African green monkeys but did have detectable viral RNA at 6 dpc in the ferret study. Although we did not detect circulating viral RNA in the African green monkeys, the increase of neutralizing antibody titers at the study endpoint suggests sterilizing immunity was not achieved, and dosing or regimen will require further testing to reach sterilizing immunity with this single-round replication vaccine vector.</p>
              <p>The single-round replication rVSV NiV vectors in this study and the replication competent rVSV-EBOV-GP-NiVG (<xref rid="R23" ref-type="bibr"><italic>23</italic></xref>) are the only vaccine vectors to show 100% single-dose vaccine efficacy against NiV in the African green monkey model. Although both studies used this model, they differed in several ways. Our study used NiV<sub>B</sub> and challenged through the intratracheal and intranasal routes, whereas the other study used NiV<sub>M</sub> by the intratracheal route only (intratracheal challenge route used in initial model [<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>]). Here, we report detectable levels of NiV RNA in nasal swab samples at early times postchallenge, whereas the rVSV-EBOV-GP-NiVG study did not report any detectable NiV RNA in nasal swab samples. Whether these differences resulted from use of the intranasal route as part of the challenge cannot be determined here; however, neither study reported circulating levels of NiV RNA, indicating the prevention of systemic spread of NiV infection. Both studies reported the detection of circulating neutralizing antibodies on the day of challenge (28 [this study] and 29 days postvaccination). However, we reported on PFU reduction, and the rVSV-EBOV-GP-NiVG study reported on reduction of 200 50% tissue culture infectious dose in a tissue culture infectious dose assay, so the peak neutralizing titers at NiV challenge cannot be directly compared. </p>
              <p>The PRNT<sub>50</sub> titers we reported can be directly compared with the recombinant subunit sG<sub>HeV</sub> vaccine NiV study in African green monkeys that also was 100% efficacious (<xref rid="R29" ref-type="bibr"><italic>29</italic></xref>), whereas we detected higher PRNT<sub>50</sub> titers against NiV from the single injection of single-round replication vectors (from 160 to 640; <xref rid="T1" ref-type="table">Table 1</xref>) versus the PRNT<sub>50</sub> titers 2 weeks after boost vaccination (from 28 to 379) for the recombinant subunit sG<sub>HeV</sub> vaccine. However, these lower titers most likely are due to the sG<sub>HeV</sub> vaccine being heterotypic because the PRNT<sub>50</sub> titers against HeV in a similar African green monkey study were 640–1,280 on day of challenge (<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>). The development of neutralizing antibodies to the NiV glycoproteins after vaccination are important for protection, as highlighted by a single monoclonal antibody against the henipavirus G protein, m102.4, that is 100% protective against HeV, NiV<sub>M</sub>, and NiV<sub>B</sub> when administered at least 3 dpc (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>,<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>,<xref rid="R35" ref-type="bibr"><italic>35</italic></xref>). </p>
              <p>In our study, the F cohort did not produce as consistent a neutralizing antibody titer response as did the G and F/G cohorts. Further analysis also revealed that, although no major changes occurred in hematologic and blood chemistry results for any of the vaccine cohorts, minor changes occurred in the F and F/G cohorts (<xref rid="T1" ref-type="table">Table 1</xref>). These data, taken together with the lack of detectable NiV<sub>B</sub> RNA in the oral swab samples of the G group, suggest the rVSV NiV G vector might be the better option among the 3 vaccine vectors.</p>
              <p>In summary, we found that single-round replication rVSV vectors against NiV<sub>B</sub> provided 100% efficacy against NiV<sub>B</sub> challenge using a single-dose regimen. The rVSV vaccine platform has received attention recently because the replication-competent rVSV-ZEBOV GP vaccine vector against EBOV has now been given to &gt;16,000 humans in clinical trials ranging from phase 1 to phase 3 and has been safe and efficacious (<xref rid="R36" ref-type="bibr"><italic>36</italic></xref>); however, data for pregnant women and immunocompromised persons are not yet available. A single-round replication rVSV vaccine vector that is immunogenic and efficacious would have an attractive safety profile. Whether these single-round replication rVSV NiV vaccine vectors are as safe as the recombinant subunit sG<sub>HeV</sub> vaccine has yet to be determined, and the subunit vaccine has yet to be tested with a single-dose vaccine regimen. Although multidose vaccine regimens would be a potential strategy for laboratory and healthcare workers and for first responders in stable settings with defined risk for an NiV outbreak, an outbreak setting or a case of deliberate release of NiV would require rapid protection with a single administration of vaccine. The single-dose strategy was successfully enacted using a close-contact ring vaccination strategy with the rVSV-ZEBOV-GP vaccine at the end of the 2013–2016 EBOV epidemic (<xref rid="R37" ref-type="bibr"><italic>37</italic></xref>–<xref rid="R39" ref-type="bibr"><italic>39</italic></xref>). The strategy was so successful that it became the World Health Organization recommendation for future EBOV outbreaks and has recently been set into motion in the ongoing outbreak in the Democratic Republic of the Congo (<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>). Recent studies also suggest that the ring vaccination strategy for viruses such as EBOV (depending on transmissibility) that are endemic to countries that might not be able to afford a mass herd-immunity vaccination strategy might be more effective than mass vaccinations at controlling outbreaks (<xref rid="R41" ref-type="bibr"><italic>41</italic></xref>). Further studies should examine the time to immunity of the G<sub>Ind</sub>* rVSV-ΔG-NiV<sub>B</sub>/G in the NiV<sub>B</sub> African green monkey model because these data will be instrumental in providing information about whether this vaccine vector could be implemented in a ring vaccination strategy during future NiV outbreaks, such as the current one in India (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>).</p>
            </sec>
            <sec sec-type="supplementary-material">
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <caption>
                  <title>Appendix</title>
                  <p>Additional methods for study on use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal Nipah virus disease.</p>
                </caption>
                <media xlink:href="18-1620-Techapp-s1.pdf" id="d95e1162" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank the staff of the University of Texas Medical Branch Animal Resources Center for animal husbandry, Robert W. Cross for assistance with the animal study, and Natalie Dobias for assistance with histologic processing. We thank Thomas G. Ksiazek for kindly providing the NiV<sub>B</sub> isolate used in this study. </p>
              <p>This study was supported in part by National Institutes of Health (U01 AI082121 for research and UC7AI094660 for BSL-4 operations) and by funds provided to T.W.G. by the UTMB Department of Microbiology and Immunology.</p>
            </ack>
            <fn-group>
              <fn fn-type="citation">
                <p><italic>Suggested citation for this article</italic>: Mire CE, Geisbert JB, Agans KN, Versteeg KM, Deer DJ, Satterfield BA, et al. Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal Nipah virus disease. Emerg Infect Dis. 2019 Jun [<italic>date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid2506.181620" ext-link-type="uri">https://doi.org/10.3201/eid2506.181620</ext-link></p>
              </fn>
              <fn id="FN1">
                <label>1</label>
                <p>Current affiliation: Mayo Clinic, Rochester, Minnesota, USA.</p>
              </fn>
            </fn-group>
            <bio id="d95e1183">
              <p>Dr. Mire is an associate professor in the Department of Microbiology and Immunology at the University of Texas Medical Branch–Galveston and the Galveston National Laboratory. His research focuses on understanding host–pathogen interactions of highly pathogenic RNA viruses.</p>
            </bio>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Harcourt</surname><given-names>BH</given-names></string-name>, <string-name><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name><surname>Tamin</surname><given-names>A</given-names></string-name>, <string-name><surname>Rota</surname><given-names>PA</given-names></string-name>, <string-name><surname>Bellini</surname><given-names>WJ</given-names></string-name>, <etal>et al.</etal><article-title>Molecular biology of Hendra and Nipah viruses.</article-title><source>Microbes Infect</source>. <year>2001</year>;<volume>3</volume>:<fpage>279</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/S1286-4579(01)01381-8</pub-id><?supplied-pmid 11334745?><pub-id pub-id-type="pmid">11334745</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Chatterjee</surname><given-names>P</given-names></string-name>. <article-title>Nipah virus outbreak in India.</article-title><source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>2200</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31252-2</pub-id><pub-id pub-id-type="pmid">31876482</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Halpin</surname><given-names>K</given-names></string-name>, <string-name><surname>Hyatt</surname><given-names>AD</given-names></string-name>, <string-name><surname>Fogarty</surname><given-names>R</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>D</given-names></string-name>, <string-name><surname>Bingham</surname><given-names>J</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>JH</given-names></string-name>, <etal>et al.</etal>; <collab>Henipavirus Ecology Research Group</collab>. <article-title>Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission.</article-title><source>Am J Trop Med Hyg</source>. <year>2011</year>;<volume>85</volume>:<fpage>946</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.2011.10-0567</pub-id><?supplied-pmid 22049055?><pub-id pub-id-type="pmid">22049055</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Bossart</surname><given-names>KN</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>D</given-names></string-name>, <string-name><surname>Klippel</surname><given-names>J</given-names></string-name>, <string-name><surname>Crameri</surname><given-names>G</given-names></string-name>, <string-name><surname>Bingham</surname><given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.</article-title><source>PLoS Pathog</source>. <year>2009</year>;<volume>5</volume>:<elocation-id>e1000642</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000642</pub-id><?supplied-pmid 19888339?><pub-id pub-id-type="pmid">19888339</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Geisbert</surname><given-names>TW</given-names></string-name>, <string-name><surname>Daddario-DiCaprio</surname><given-names>KM</given-names></string-name>, <string-name><surname>Hickey</surname><given-names>AC</given-names></string-name>, <string-name><surname>Smith</surname><given-names>MA</given-names></string-name>, <string-name><surname>Chan</surname><given-names>YP</given-names></string-name>, <string-name><surname>Wang</surname><given-names>LF</given-names></string-name>, <etal>et al.</etal><article-title>Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.</article-title><source>PLoS One</source>. <year>2010</year>;<volume>5</volume>:<elocation-id>e10690</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0010690</pub-id><?supplied-pmid 20502528?><pub-id pub-id-type="pmid">20502528</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Hooper</surname><given-names>P</given-names></string-name>, <string-name><surname>Zaki</surname><given-names>S</given-names></string-name>, <string-name><surname>Daniels</surname><given-names>P</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>D</given-names></string-name>. <article-title>Comparative pathology of the diseases caused by Hendra and Nipah viruses.</article-title><source>Microbes Infect</source>. <year>2001</year>;<volume>3</volume>:<fpage>315</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/S1286-4579(01)01385-5</pub-id><?supplied-pmid 11334749?><pub-id pub-id-type="pmid">11334749</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Wong</surname><given-names>KT</given-names></string-name>, <string-name><surname>Grosjean</surname><given-names>I</given-names></string-name>, <string-name><surname>Brisson</surname><given-names>C</given-names></string-name>, <string-name><surname>Blanquier</surname><given-names>B</given-names></string-name>, <string-name><surname>Fevre-Montange</surname><given-names>M</given-names></string-name>, <string-name><surname>Bernard</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>A golden hamster model for human acute Nipah virus infection.</article-title><source>Am J Pathol</source>. <year>2003</year>;<volume>163</volume>:<fpage>2127</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)63569-9</pub-id><?supplied-pmid 14578210?><pub-id pub-id-type="pmid">14578210</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Chua</surname><given-names>KB</given-names></string-name>, <string-name><surname>Bellini</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Rota</surname><given-names>PA</given-names></string-name>, <string-name><surname>Harcourt</surname><given-names>BH</given-names></string-name>, <string-name><surname>Tamin</surname><given-names>A</given-names></string-name>, <string-name><surname>Lam</surname><given-names>SK</given-names></string-name>, <etal>et al.</etal><article-title>Nipah virus: a recently emergent deadly paramyxovirus.</article-title><source>Science</source>. <year>2000</year>;<volume>288</volume>:<fpage>1432</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.288.5470.1432</pub-id><?supplied-pmid 10827955?><pub-id pub-id-type="pmid">10827955</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Uppal</surname><given-names>PK</given-names></string-name>. <article-title>Emergence of Nipah virus in Malaysia.</article-title><source>Ann N Y Acad Sci</source>. <year>2000</year>;<volume>916</volume>:<fpage>354</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05312.x</pub-id><?supplied-pmid 11193645?><pub-id pub-id-type="pmid">11193645</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Ching</surname><given-names>PKG</given-names></string-name>, <string-name><surname>de los Reyes</surname><given-names>VC</given-names></string-name>, <string-name><surname>Sucaldito</surname><given-names>MN</given-names></string-name>, <string-name><surname>Tayag</surname><given-names>E</given-names></string-name>, <string-name><surname>Columna-Vingno</surname><given-names>AB</given-names></string-name>, <string-name><surname>Malbas</surname><given-names>FF</given-names><suffix>Jr</suffix></string-name>, <etal>et al.</etal><article-title>Outbreak of henipavirus infection, Philippines, 2014.</article-title><source>Emerg Infect Dis</source>. <year>2015</year>;<volume>21</volume>:<fpage>328</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.3201/eid2102.141433</pub-id><?supplied-pmid 25626011?><pub-id pub-id-type="pmid">25626011</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Gurley</surname><given-names>ES</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bell</surname><given-names>M</given-names></string-name>, <string-name><surname>Azad</surname><given-names>AK</given-names></string-name>, <string-name><surname>Islam</surname><given-names>MR</given-names></string-name>, <etal>et al.</etal><article-title>Person-to-person transmission of Nipah virus in a Bangladeshi community.</article-title><source>Emerg Infect Dis</source>. <year>2007</year>;<volume>13</volume>:<fpage>1031</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3201/eid1307.061128</pub-id><?supplied-pmid 18214175?><pub-id pub-id-type="pmid">18214175</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Harcourt</surname><given-names>BH</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>L</given-names></string-name>, <string-name><surname>Tamin</surname><given-names>A</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Bankamp</surname><given-names>B</given-names></string-name>, <string-name><surname>Bowden</surname><given-names>N</given-names></string-name>, <etal>et al.</etal><article-title>Genetic characterization of Nipah virus, Bangladesh, 2004.</article-title><source>Emerg Infect Dis</source>. <year>2005</year>;<volume>11</volume>:<fpage>1594</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3201/eid1110.050513</pub-id><?supplied-pmid 16318702?><pub-id pub-id-type="pmid">16318702</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Hsu</surname><given-names>VP</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Parashar</surname><given-names>UD</given-names></string-name>, <string-name><surname>Ali</surname><given-names>MM</given-names></string-name>, <string-name><surname>Ksiazek</surname><given-names>TG</given-names></string-name>, <string-name><surname>Kuzmin</surname><given-names>I</given-names></string-name>, <etal>et al.</etal><article-title>Nipah virus encephalitis reemergence, Bangladesh.</article-title><source>Emerg Infect Dis</source>. <year>2004</year>;<volume>10</volume>:<fpage>2082</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3201/eid1012.040701</pub-id><?supplied-pmid 15663842?><pub-id pub-id-type="pmid">15663842</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Lo</surname><given-names>MK</given-names></string-name>, <string-name><surname>Lowe</surname><given-names>L</given-names></string-name>, <string-name><surname>Hummel</surname><given-names>KB</given-names></string-name>, <string-name><surname>Sazzad</surname><given-names>HM</given-names></string-name>, <string-name><surname>Gurley</surname><given-names>ES</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>MJ</given-names></string-name>, <etal>et al.</etal><article-title>Characterization of Nipah virus from outbreaks in Bangladesh, 2008-2010.</article-title><source>Emerg Infect Dis</source>. <year>2012</year>;<volume>18</volume>:<fpage>248</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.3201/eid1802.111492</pub-id><?supplied-pmid 22304936?><pub-id pub-id-type="pmid">22304936</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Luby</surname><given-names>SP</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Gurley</surname><given-names>ES</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>BN</given-names></string-name>, <string-name><surname>Banu</surname><given-names>S</given-names></string-name>, <string-name><surname>Khan</surname><given-names>SU</given-names></string-name>, <etal>et al.</etal><article-title>Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007.</article-title><source>Emerg Infect Dis</source>. <year>2009</year>;<volume>15</volume>:<fpage>1229</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.3201/eid1508.081237</pub-id><?supplied-pmid 19751584?><pub-id pub-id-type="pmid">19751584</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Homaira</surname><given-names>N</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>JH</given-names></string-name>, <string-name><surname>Sultana</surname><given-names>R</given-names></string-name>, <string-name><surname>Khan</surname><given-names>MS</given-names></string-name>, <etal>et al.</etal><article-title>Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007.</article-title><source>Epidemiol Infect</source>. <year>2010</year>;<volume>138</volume>:<fpage>1630</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268810000695</pub-id><?supplied-pmid 20380769?><pub-id pub-id-type="pmid">20380769</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Guillaume</surname><given-names>V</given-names></string-name>, <string-name><surname>Contamin</surname><given-names>H</given-names></string-name>, <string-name><surname>Loth</surname><given-names>P</given-names></string-name>, <string-name><surname>Georges-Courbot</surname><given-names>MC</given-names></string-name>, <string-name><surname>Lefeuvre</surname><given-names>A</given-names></string-name>, <string-name><surname>Marianneau</surname><given-names>P</given-names></string-name>, <etal>et al.</etal><article-title>Nipah virus: vaccination and passive protection studies in a hamster model.</article-title><source>J Virol</source>. <year>2004</year>;<volume>78</volume>:<fpage>834</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.78.2.834-840.2004</pub-id><?supplied-pmid 14694115?><pub-id pub-id-type="pmid">14694115</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Weingartl</surname><given-names>HM</given-names></string-name>, <string-name><surname>Berhane</surname><given-names>Y</given-names></string-name>, <string-name><surname>Caswell</surname><given-names>JL</given-names></string-name>, <string-name><surname>Loosmore</surname><given-names>S</given-names></string-name>, <string-name><surname>Audonnet</surname><given-names>J-C</given-names></string-name>, <string-name><surname>Roth</surname><given-names>JA</given-names></string-name>, <etal>et al.</etal><article-title>Recombinant nipah virus vaccines protect pigs against challenge.</article-title><source>J Virol</source>. <year>2006</year>;<volume>80</volume>:<fpage>7929</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00263-06</pub-id><?supplied-pmid 16873250?><pub-id pub-id-type="pmid">16873250</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Ploquin</surname><given-names>A</given-names></string-name>, <string-name><surname>Szécsi</surname><given-names>J</given-names></string-name>, <string-name><surname>Mathieu</surname><given-names>C</given-names></string-name>, <string-name><surname>Guillaume</surname><given-names>V</given-names></string-name>, <string-name><surname>Barateau</surname><given-names>V</given-names></string-name>, <string-name><surname>Ong</surname><given-names>KC</given-names></string-name>, <etal>et al.</etal><article-title>Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.</article-title><source>J Infect Dis</source>. <year>2013</year>;<volume>207</volume>:<fpage>469</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis699</pub-id><?supplied-pmid 23175762?><pub-id pub-id-type="pmid">23175762</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Lo</surname><given-names>MK</given-names></string-name>, <string-name><surname>Bird</surname><given-names>BH</given-names></string-name>, <string-name><surname>Chattopadhyay</surname><given-names>A</given-names></string-name>, <string-name><surname>Drew</surname><given-names>CP</given-names></string-name>, <string-name><surname>Martin</surname><given-names>BE</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>JD</given-names></string-name>, <etal>et al.</etal><article-title>Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.</article-title><source>Antiviral Res</source>. <year>2014</year>;<volume>101</volume>:<fpage>26</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.10.012</pub-id><?supplied-pmid 24184127?><pub-id pub-id-type="pmid">24184127</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name><surname>Versteeg</surname><given-names>KM</given-names></string-name>, <string-name><surname>Cross</surname><given-names>RW</given-names></string-name>, <string-name><surname>Agans</surname><given-names>KN</given-names></string-name>, <string-name><surname>Fenton</surname><given-names>KA</given-names></string-name>, <string-name><surname>Whitt</surname><given-names>MA</given-names></string-name>, <etal>et al.</etal><article-title>Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.</article-title><source>Virol J</source>. <year>2013</year>;<volume>10</volume>:<fpage>353</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-10-353</pub-id><?supplied-pmid 24330654?><pub-id pub-id-type="pmid">24330654</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22. </label>
                <mixed-citation publication-type="journal"><string-name><surname>DeBuysscher</surname><given-names>BL</given-names></string-name>, <string-name><surname>Scott</surname><given-names>D</given-names></string-name>, <string-name><surname>Marzi</surname><given-names>A</given-names></string-name>, <string-name><surname>Prescott</surname><given-names>J</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>H</given-names></string-name>. <article-title>Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.</article-title><source>Vaccine</source>. <year>2014</year>;<volume>32</volume>:<fpage>2637</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.087</pub-id><?supplied-pmid 24631094?><pub-id pub-id-type="pmid">24631094</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Prescott</surname><given-names>J</given-names></string-name>, <string-name><surname>DeBuysscher</surname><given-names>BL</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Gardner</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Haddock</surname><given-names>E</given-names></string-name>, <string-name><surname>Martellaro</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease.</article-title><source>Vaccine</source>. <year>2015</year>;<volume>33</volume>:<fpage>2823</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.089</pub-id><?supplied-pmid 25865472?><pub-id pub-id-type="pmid">25865472</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Yoneda</surname><given-names>M</given-names></string-name>, <string-name><surname>Georges-Courbot</surname><given-names>M-C</given-names></string-name>, <string-name><surname>Ikeda</surname><given-names>F</given-names></string-name>, <string-name><surname>Ishii</surname><given-names>M</given-names></string-name>, <string-name><surname>Nagata</surname><given-names>N</given-names></string-name>, <string-name><surname>Jacquot</surname><given-names>F</given-names></string-name>, <etal>et al.</etal><article-title>Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.</article-title><source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<elocation-id>e58414</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0058414</pub-id><?supplied-pmid 23516477?><pub-id pub-id-type="pmid">23516477</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Mungall</surname><given-names>BA</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>D</given-names></string-name>, <string-name><surname>Crameri</surname><given-names>G</given-names></string-name>, <string-name><surname>Bingham</surname><given-names>J</given-names></string-name>, <string-name><surname>Halpin</surname><given-names>K</given-names></string-name>, <string-name><surname>Russell</surname><given-names>G</given-names></string-name>, <etal>et al.</etal><article-title>Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.</article-title><source>J Virol</source>. <year>2006</year>;<volume>80</volume>:<fpage>12293</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01619-06</pub-id><?supplied-pmid 17005664?><pub-id pub-id-type="pmid">17005664</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Pallister</surname><given-names>J</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>LF</given-names></string-name>, <string-name><surname>Klein</surname><given-names>R</given-names></string-name>, <string-name><surname>Haining</surname><given-names>J</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.</article-title><source>Vaccine</source>. <year>2011</year>;<volume>29</volume>:<fpage>5623</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.015</pub-id><?supplied-pmid 21689706?><pub-id pub-id-type="pmid">21689706</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Pallister</surname><given-names>JA</given-names></string-name>, <string-name><surname>Klein</surname><given-names>R</given-names></string-name>, <string-name><surname>Arkinstall</surname><given-names>R</given-names></string-name>, <string-name><surname>Haining</surname><given-names>J</given-names></string-name>, <string-name><surname>Long</surname><given-names>F</given-names></string-name>, <string-name><surname>White</surname><given-names>JR</given-names></string-name>, <etal>et al.</etal><article-title>Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months.</article-title><source>Virol J</source>. <year>2013</year>;<volume>10</volume>:<fpage>237</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-10-237</pub-id><?supplied-pmid 23867060?><pub-id pub-id-type="pmid">23867060</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <string-name><surname>Agans</surname><given-names>KN</given-names></string-name>, <string-name><surname>Feng</surname><given-names>YR</given-names></string-name>, <string-name><surname>Fenton</surname><given-names>KA</given-names></string-name>, <string-name><surname>Bossart</surname><given-names>KN</given-names></string-name>, <etal>et al.</etal><article-title>A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.</article-title><source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>4624</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00005-14</pub-id><?supplied-pmid 24522928?><pub-id pub-id-type="pmid">24522928</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Bossart</surname><given-names>KN</given-names></string-name>, <string-name><surname>Rockx</surname><given-names>B</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Brining</surname><given-names>D</given-names></string-name>, <string-name><surname>Scott</surname><given-names>D</given-names></string-name>, <string-name><surname>LaCasse</surname><given-names>R</given-names></string-name>, <etal>et al.</etal><article-title>A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.</article-title><source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>:<elocation-id>146ra107</elocation-id>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3004241</pub-id><?supplied-pmid 22875827?><pub-id pub-id-type="pmid">22875827</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name><surname>Satterfield</surname><given-names>BA</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <string-name><surname>Agans</surname><given-names>KN</given-names></string-name>, <string-name><surname>Borisevich</surname><given-names>V</given-names></string-name>, <string-name><surname>Yan</surname><given-names>L</given-names></string-name>, <etal>et al.</etal><article-title>Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy.</article-title><source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>30916</fpage>. <pub-id pub-id-type="doi">10.1038/srep30916</pub-id><?supplied-pmid 27484128?><pub-id pub-id-type="pmid">27484128</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Geisbert</surname><given-names>TW</given-names></string-name>, <string-name><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <string-name><surname>Chan</surname><given-names>YP</given-names></string-name>, <string-name><surname>Agans</surname><given-names>KN</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>F</given-names></string-name>, <etal>et al.</etal><article-title>Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.</article-title><source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>:<elocation-id>242ra82</elocation-id>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3008929</pub-id><?supplied-pmid 24964990?><pub-id pub-id-type="pmid">24964990</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Whitt</surname><given-names>MA</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>TW</given-names></string-name>, <string-name><surname>Mire</surname><given-names>CE</given-names></string-name>. <article-title>Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses.</article-title><source>Methods Mol Biol</source>. <year>2016</year>;<volume>1403</volume>:<fpage>295</fpage>–<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-3387-7_16</pub-id><?supplied-pmid 27076138?><pub-id pub-id-type="pmid">27076138</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Cong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lentz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Lara</surname><given-names>A</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>I</given-names></string-name>, <string-name><surname>Bartos</surname><given-names>C</given-names></string-name>, <string-name><surname>Bohannon</surname><given-names>JK</given-names></string-name>, <etal>et al.</etal><article-title>Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus.</article-title><source>PLoS Negl Trop Dis</source>. <year>2017</year>;<volume>11</volume>:<elocation-id>e0005532</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005532</pub-id><?supplied-pmid 28388650?><pub-id pub-id-type="pmid">28388650</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Johnston</surname><given-names>SC</given-names></string-name>, <string-name><surname>Briese</surname><given-names>T</given-names></string-name>, <string-name><surname>Bell</surname><given-names>TM</given-names></string-name>, <string-name><surname>Pratt</surname><given-names>WD</given-names></string-name>, <string-name><surname>Shamblin</surname><given-names>JD</given-names></string-name>, <string-name><surname>Esham</surname><given-names>HL</given-names></string-name>, <etal>et al.</etal><article-title>Detailed analysis of the African green monkey model of Nipah virus disease.</article-title><source>PLoS One</source>. <year>2015</year>;<volume>10</volume>:<elocation-id>e0117817</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0117817</pub-id><?supplied-pmid 25706617?><pub-id pub-id-type="pmid">25706617</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Bossart</surname><given-names>KN</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>TW</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Geisbert</surname><given-names>JB</given-names></string-name>, <etal>et al.</etal><article-title>A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.</article-title><source>Sci Transl Med</source>. <year>2011</year>;<volume>3</volume>:<elocation-id>105ra103</elocation-id>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3002901</pub-id><?supplied-pmid 22013123?><pub-id pub-id-type="pmid">22013123</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Suder</surname><given-names>E</given-names></string-name>, <string-name><surname>Furuyama</surname><given-names>W</given-names></string-name>, <string-name><surname>Feldmann</surname><given-names>H</given-names></string-name>, <string-name><surname>Marzi</surname><given-names>A</given-names></string-name>, <string-name><surname>de Wit</surname><given-names>E</given-names></string-name>. <article-title>The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.</article-title><source>Hum Vaccin Immunother</source>. <year>2018</year>;<volume>14</volume>:<fpage>2107</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2018.1473698</pub-id><?supplied-pmid 29757706?><pub-id pub-id-type="pmid">29757706</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Gsell</surname><given-names>PS</given-names></string-name>, <string-name><surname>Camacho</surname><given-names>A</given-names></string-name>, <string-name><surname>Kucharski</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Watson</surname><given-names>CH</given-names></string-name>, <string-name><surname>Bagayoko</surname><given-names>A</given-names></string-name>, <string-name><surname>Nadlaou</surname><given-names>SD</given-names></string-name>, <etal>et al.</etal><article-title>Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.</article-title><source>Lancet Infect Dis</source>. <year>2017</year>;<volume>17</volume>:<fpage>1276</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30541-8</pub-id><?supplied-pmid 29033032?><pub-id pub-id-type="pmid">29033032</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Henao-Restrepo</surname><given-names>AM</given-names></string-name>, <string-name><surname>Camacho</surname><given-names>A</given-names></string-name>, <string-name><surname>Longini</surname><given-names>IM</given-names></string-name>, <string-name><surname>Watson</surname><given-names>CH</given-names></string-name>, <string-name><surname>Edmunds</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).</article-title><source>Lancet</source>. <year>2017</year>;<volume>389</volume>:<fpage>505</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32621-6</pub-id><?supplied-pmid 28017403?><pub-id pub-id-type="pmid">28017403</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Henao-Restrepo</surname><given-names>AM</given-names></string-name>, <string-name><surname>Longini</surname><given-names>IM</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Dean</surname><given-names>NE</given-names></string-name>, <string-name><surname>Edmunds</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Camacho</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.</article-title><source>Lancet</source>. <year>2015</year>;<volume>386</volume>:<fpage>857</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)61117-5</pub-id><?supplied-pmid 26248676?><pub-id pub-id-type="pmid">26248676</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Wise</surname><given-names>J</given-names></string-name>. <article-title>WHO is “cautiously optimistic” about Ebola ring vaccination programme in DRC.</article-title><source>BMJ</source>. <year>2018</year>;<volume>361</volume>:<fpage>k2388</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.k2388</pub-id><?supplied-pmid 29848617?><pub-id pub-id-type="pmid">29848617</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41. </label>
                <mixed-citation publication-type="journal"><string-name><surname>Masterson</surname><given-names>SG</given-names></string-name>, <string-name><surname>Lobel</surname><given-names>L</given-names></string-name>, <string-name><surname>Carroll</surname><given-names>MW</given-names></string-name>, <string-name><surname>Wass</surname><given-names>MN</given-names></string-name>, <string-name><surname>Michaelis</surname><given-names>M</given-names></string-name>. <article-title>Herd immunity to Ebolaviruses is not a realistic target for current vaccination strategies.</article-title><source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>1025</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01025</pub-id><?supplied-pmid 29867992?><pub-id pub-id-type="pmid">29867992</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
